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Existing data on the structure of human deoxycytidine ~inase (dCK) diverge. A monomcrlc 60 kDa form has b~en isolated and th~ cloning of 
a eDNA coding for 626 amino acids correspondin$ to a ?1 kDa protein has been reported. However, pure dCK isolated ['tom leukemic spleen 
i~ a dimer of 30 kDa subanits, Amino acid sequences of i~ptides from digests of this protein arc now presented, None of the pcptide structures 
obtaincd correspond to the cDNA for the 71 kDa protein, but to a eDNA for a 30,~ kDa dCK recently cloned. Furthermore, homology of the 
pcptido sequences of dCK to parts or thymidine kinases and protein.tyrosine kinases are detected, 
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I. INTRODUCTION 
Deoxycytidine kinase (dCK; EC 2,7.1,74) catalyzes 
the phosphorylation o f deo)cycytidine to deoxycytidine 
5 ' -monophosphate using nucleoside triphosphates as 
phosphoryl donors, dCK can also phosphorylate purine 
deoxyribonucleosides and a large number of  deox- 
ynucleoside analogs, It has been clearly shown that the 
activity of dCK is a prerequisite for the antivirai and 
cytostatic effect of  several therapeutically important 
nucleoside analogs, 
dCK has been purified from many sources (reviewed 
in [1]) but it has been possible only recently to obtain 
apparently homogeneous preparations from leukemic 
spleen [2,3]. The active enzyme appeared to be a dimer 
of two 30 kDa subunits, as judged by SDS- 
polyacrylamide gel electrophoresis, gel exclusion 
chromatography and glycerol gradient centrifugation 
[3]. In accordance with these results, dCK from Molt-4 
T.lymphoblasts was reported to be a dimer of  two 30 
kDa subunits [4] However, other reports suggest [5,6] 
that nat ivedCK from human leukemic T.lymphoblasts 
is a monomer of  60 kDa when prepared in the presence 
of protease inhibitors. In the absence of protease in- 
hibitors, two fragments o f  30 and 33 kDa, were observ- 
ed, suggesting that proteolytic leavage of a 60 kDa 
dCK during purification results in two shorter 
fragments. Furthermore, the cloning and sequence 
determination of a eDNA suggested to code for human 
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dCK with 626 amino acids corresponding to a 71 kDa 
polypeptide has been reported [7], 
To resolve these discrepancies and to obtain informa- 
tion for reliable cloning of  the gene for human dCK, 
chemical characterization f the 30 kDa Iluman spleen 
enzyme is essential, Here, we present data on the total 
composition of the protein and on peptide sequences of 
four segments. A correlation of these results with those 
published before [7] and with a very recent eDNA se- 
quence for human dCK [8] resolves the question and 
unambiguously identifies the correct dCK structure, 
2. MATERIALS AND METHODS 
Human leukemic dCK was prepared as described [3], The final 
preparation had a specific activity of 200 nmol dCMP form- 
cd/min/mg and was more than 95°70 pure as judged by SDS- 
polyacrylamide g lelectrophoresis, 
For analysis, protein (3-300/~g) was precipitated with :200/0 TCA (1 
h on ice), washed twice with - 20°C acetone, lyophilized, issolved in
500 #1 8 M urea, 0,4 M Tris HCI, pH 8,5, 2 mM EDTA, Reduction 
was performed with 5 mM DTT (2 h at 37°C), after which the protein 
was carboxymethylated by addition of L4C-labeled iodoacetate (IS 
raM) and incubated for 90 rain at 37°C anaerobically in the dark, The 
reaction was stopped by addition of excess mercaptoethanol andthe 
sample desalted on Sephadex GS0 eluted with 3001o acetic acid, After 
lyophilization the protein was dissolved in 1.0 ml 7007o formic acid 
containing 0,2 g CNBr for methionine cleavage at25°C for 24 h or 
dissolved in 8 M deionized urea, in 0.2 M ammonium bicarbonate, pH 
8.0, and subsequently diluted to a final concentration of I M urea, 0.2 
M ammonium bicarbonate for Lys-specific cleavage with Lys C- 
endoprotease (Boehringer), 4 h at 37°C with a protein:protease ratio 
of 10:1, 
CNBr fragments were separated by HPLC on a ~Bondapak C~s col- 
umn developed with a linear gradient of 0-80°70 acetonitrile in 0.1070 
aqueous trifluoroacetic a id for 80 min at a flow rate of 1 ml/min, 
while the Lys-cleaved peptides were separated ona Vydac Cts column 
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T~I~ I 
Total ¢ompt3~hlon of the lit.linen deoxyeytldtne kln~te ~.~l?;eed 
Pr, esent dlre~t protein an#ly~i~ eDNA .n~l),~i~ 
Residue mol/mol [e I 171 
Cy~ 4.4 6 6 
A~x 20.4 24 71 
Tier 16. I I$ 2~ 
Set 24.0 20 34 
GIx 42.7 40 ~0 
Pro 9.9 I0 39 
GIy 18.0 11 32 
Ala 16. I II 48 
V~I 9.1 ~ 12 54 
Met 4.8 6 I~ 
lie 7.3 ~ 13 29 
Leu 21.8 27 47 
Tyr I I, 12 27 
Phe I I.? 12 30 
Trp 4.7 ~ 7 6 
Lys I 7, I I 7 60 
His 4.8 5 7 
~rg 13.2 12 23 
T¢lal 257 260 626 
Values shown are molar ratios as determined by PTC analysis after 
acid hydrolysis, For comparison the values corresponding to those 
derived from th© intial [71 and tile recent [81 eDNA reports arc also 
given, showing the disagreement of the former but agreement of the 
latter witl~ the present direct protein analysis. 
Value obtained after hydrolysis with methane sulfonic acid 
Low yields upon acid hydrolysis was due to ~he presence of VaI.Val 
and lie-lie sequences [8] 
developed with a linear gradient of 0-60% acctonitrile in 0,1% 
trifluoroacelic acid for 75 rain at I ml/min. 
2.1. Structural analysts 
Sequencer degradations were performed with Applied Biosystems 
470A and 477A instruments. Phenylthiohydantoin derivatives were 
analyzed by HPLC using a sodium acetate/acetonitrile gradient on a 
Hewlett-Packard 1090 instrument [9] or the ot~-Iine Applied 
Biosystems 120A system, Total compositions were determined after 
PTC-modification of the amino acids as described [10]. 
3. RESULTS 
3.1. Protein characterization 
The amino acid composition of human dCK after af- 
finity chromatography is shown in Table I. N-terminal 
sequence analysis of 400 pmol showed no significant 
amino acid residue for the first 4 cycles, suggesting that 
the N-terminus of dCI( is blocked. 
Reduced and carboxymethylated dCK (approximate- 
ly 5 nmol) was cleaved with CNBr. Resulting peptides 
were separated by reverse-phase HPLC (Fig. IA) and 
two peaks were analyzed for amino acid sequence. One 
(CI) was sufficiently pure for interpretation for 18 
cycles (Fig. 1A), while the other (main peptide peak) 
contained at least hree different peptides and could not 
be reliably interpreted. Another batch of dCK was sub- 
jected to digestion with the Lys-specific protease and 
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Fig, I, [-IPLC chromatograms and amino acid sec~tlences determined 
for peptides resulting from (A) CNBr cleavage and (B) Lys.specific 
cleavage of purified human dCK, Numbering of amino acid residues 
is that deduced from the eDNA sequence of Chottiner et al. [8] using 
the initiator methionine as position one. X denotes an incompletely 
identified amino acid residue, 
fractionated by HPLC (Fig. IB). The results of amino 
acid sequence analysis of peptides (LI, L2, L3) from 
this digest are shown in Fig. lB. 
3:2. Correlation with eDNA sequences 
Surprisingly, none of the sequences (C1, L1, L2 or 
L3; Fig, 1A and B) showed more than 20% identity to 
any peptide sequence deduced from a previous eDNA 
clone [7], nor could the amino acid composition ow 
determined be correlated with that of the entire 71 kDa 
peptide, of. Table I [7] or its C-terminal or N-terminal 
halves. 
After the completion of this analysis a second eDNA 
corresponding to dCK was cloned from a human T-cell 
library [8]. This clone could be used to transfect dCK 
negative mouse L-cells such that the transfectants ex- 
pressed an active riCK. The deduced amino acid se- 
quence contained 260 amino acid residues, correspon- 
ding to a protein of 30.5 kDa. 
We could identify all our peptide sequences in the 
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deduced amino acid sequence of this new report [81 and 
the numbering of the amino acids in Fie, I refers to the 
positions in that eDNA.derived seqaence with the in- 
itiator methionine as position one (Fig, 1), 
In searches for sequence homology between the dCK 
peptides and other deoxynucleoside kinases characteriz. 
ed [12-14], we found a segment in peptide LI that 
showed homology to a suggested trlphosphate binding 
domain in the N.terminal part of human and mouse 
thymidin¢ kinases 1 (Fig. 2A). Similarly, in peptide L3 
a structure isobserved that is homologous tothe very C. 
terminal part of several human protein.tyrosine kinase 
oncogenes [t3,151 (Fig, 2B), 
4. DISCUSSION 
A chemical characterization f leukemic 30 kDa, 
dCK was performed. We found the N,terminus to be 
blocked and therefore produced internal fragments by 
cleavage with CNBr and Lys-specific protease. After 
HPLC purification, several peptide sequences were 
determined. During the completion of this work a 
eDNA sequence of human dCK. was published [7]. Sur- 
prisingly, no significant homology was found between 
that sequence and any of the peptide sequences obtain. 
ed from the pure enzyme. Furthermore, the molecular 
weight of the cloned eDNA corresponded to a peptide 
of 71 kDa and we could not correlate this or the amino 
acid composition deduced with that of the protein we 
analyzed, Neither could the leukemic dCK be a pro- 
teolytic fragment of the larger protein as judged from 
the total composition. 
Hence, we conclude that the previous eDNA report 
[7] concerns a protein different from dCK as recently 
also confirmed by Huang et al. [11], showing the 71 
kDa protein to be a human stress protein homologous 
to murme ERp72. 
However, very recently Chottiner et al. [8] have clan- 
HUMAN TK 3~ELMRRV 
M0us  TK    STELMR V 
LI dCK 34K~FVNILK 
Human c-src 
Human c-fgr 
.CK-JURKAT 
L3 dCK 
506RPT~EHAFLEDYFTSTEPQYQPGENL 
RP TIF~EIY LqISFL EDY FTSAEPQYQPGDOT 
R P TIF-DY L~S~L E DF FTAT EGQ Y QPQ P 
222KTN[FDYLQ]EV~PILTL 
Fig. 2. Possible sequence homology (A) of peptide LI with human 
and mouse thymidine kinases (TK:s) [12,14] and (B) peptide L3 with 
tl~e C-terminal part of  members of the src-subfamlly of protein 
tyrosine.kinases [13,16], The abbreviations u ed are explained in the 
text. Lys before LI and L3 is shown because a Lys-specific protease 
was used to generate these peptides. Bo×es indicate residue identities 
between characterized proteins and LI or L3. 
ed and  sequenced a eDNA which can be used to 
transfect mouse dCK-ne=ative cells and confer an active 
enzyme to the transfectants, This eDNA codes for a 
protein correspondinB to a 30,S kDa polypeptide [8]. 
The deduced protein sequence does contain the four 
peptide sequences now described from pure leukemic 
riCK, and the amino acid composition deduced from 
the cloned eDNA aarees with that experimentally deter- 
mined (Table l), Our data demonstrate that the eDNA 
cloned by Chottiner et al, indeed codes for the leukemic 
30 kDa dCK now analyzed, and already previously 
isolated [3]. The fact that the eDNA.deduced molecular 
weight asrees with the one determined for the purified 
enzyme argues against major post-translational 
modifications of human dCK, 
It is reasonable toassume that there will be regions of 
sequence homology between different nucleoside 
kinascs. One such region, called the phosphate binding 
loop, has been identified in all known thymidine 
kinases and in a large number of the ATP binding pro- 
teins, e.g. protein kinases [12,13], Peptide Li appears 
to be homologous to part of this highly conserved 
region as shown in Fig, 2A where these sequences of 
human and mouse thymidine kinases are compared to 
that of LI [12-15]. The sequence KST is found in all 
thymidine kinases and probably forms the first three 
amino acid residues in an c~.helix that terminates the 
phosphate loop [13]. This hypothesis is based on 
models which have been constructed using the known 
structure of adenylate kinase to predict he structure of 
this region of the nucleoside kinases [14], When the se- 
quences of L2 and C 1 were cam pared to other kinase se- 
quences no significant homologies were apparent. 
However, the sequence LDG was found in human and 
mouse TK:s, starting at position 130, as well as in Cl 
but no other conserved amino acids were found in this 
peptide. 
Another homology was detected in the L3 peptide 
which was found in the C-terminal part of the eDNA- 
deduced sequence [8] and showed homology to the very 
C.terminal part of the src-subfamily of protein-tyrosine 
kinases [13,16]. This proto-oncogene family, in addi- 
tion to the cellular homologies of the oncogene pro- 
ducts from gous avian sarcoma (src), Gardner-Rasheed 
feline sarcoma (fgr) and the lymphoid cell protein- 
tyrosine kinase (LCK-JURKAT) also consists of several 
protein kinases with extensive similarities in primary 
structure. This part of the protein-tyrosine kinases cor- 
responds to the subdomain XI in the nomenclature of
Hanks et al. [13]. Arg at position 506 (Fig. 2B) is a 
residue that is conserved not only in this family but 
among all 65 protein kinases listed by Hanks et al, This 
region is located near the carboxyl-terminus of the 
catalytic domain but its function in protein kinases is 
thus far not known. These results indicate that dCK is 
part of a nucleoside kinase family that also may show 
structural similarity to the protein kinase family. 
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